Table 1.
Case reports of renal transplant recipients receiving ICI therapy for metastatic melanoma
| Case | Immune checkpoint inhibitor | Age | Sex | Kidney disease | Kidney transplantation | Melanoma diagnosis (year diagnosed) |
Site of metastases (year diagnosed) |
Immunosuppression before initiation of ICI | Allograft rejection | Time interval from ICI to rejection | Treatment duration | Treatment response |
| This case | Nivolumab alone | 71 | F | Chronic primary pyelonephritis | 2003 | 1.6 mm superficial spreading melanoma (2016) | Lung and scalp | Tacrolimus and prednisolone | Acute T cell mediated rejection | 15 days | Ongoing | Complete response |
| Ong et al26 | 63 | F | Hypertension and diabetes mellitus | 2004 | 2.59 mm melanoma | Lung and hilar lymph nodes | Prednisolone | Acute T cell mediated rejection | 8 days | Ongoing | Partial response | |
| Winkler et al27 | 60 | F | Polycystic kidney disease | 2003 | Metastatic melanoma (2014) | Lung, brain and intrathoracic lymph nodes (2016) | Prednisolone and mycophenolate mofetil | No rejection | NIL | Four doses | Disease progression | |
| Tio et al28 | 48 | M | NR | NR | Metastatic melanoma | NR | Tacrolimus and prednisolone | Acute T cell mediated rejection | NR | One dose | Partial response | |
| Deltombe et al29 | 73 | M | NR | NR | Superficial spreading melanoma | NR | Everolimus | Acute T cell mediated rejection | 85 days | Two doses | Disease progression | |
| Winkler et al27 | Pembrolizumab alone | 58 | M | Hydronephrosis | 1982 | Uveal melanoma (2013) | Lung, liver and bone (2015) | Cyclosporine | No rejection | NIL | Four doses | Disease progression |
| Kwatra et al30 | 58 | M | IgM nephropathy | 2001 | 21 mm ulcerated nodular melanoma | Liver, bone, hilar lymph nodes and porta hepatis lymph nodes | Azathioprine and everolimus | Rejection | 42 days | Two doses | Disease progression | |
| Tio et al28 | 70 | M | NR | NR | Metastatic melanoma | NR | Tacrolimus and prednisolone | No rejection | NIL | NR | Disease progression | |
| Tio et al28 | 75 | M | NR | NR | Metastatic melanoma | NR | Prednisolone | No rejection | NIL | NR | Partial response | |
| Tio et al28 | 65 | M | NR | NR | Metastatic melanoma | NR | Prednisolone, mycophenolate mofetil, tacrolimus | No rejection | NIL | NR | Disease progression | |
| Winkler et al27 | 58 | M | Hydronephrosis | 1982 | Uveal melanoma (2013) | Lung, liver and bone (2015) | Cyclosporine | No rejection | NIL | Four doses | Disease progression | |
| Lipson et al31 | Ipilimumab alone | 72 | M | Hypertension | 2000 | 8 mm ulcerated melanoma (2008) | Left axillary lymph nodes | Prednisolone | No rejection | NIL | NR | Complete response |
| Lipson et al31 | 58 | M | Polycystic kidney disease | 2004 | 4.2 mm nodular melanoma (2011) | Lung, right neck lymph nodes and mesenteric lymph nodes | Prednisolone | No rejection | NIL | Four doses | Disease progression | |
| Jose et al32 | 40 | M | NR | 1997 | Ocular melanoma (2013) | Liver (2013) | Prednisolone | Acute T cell mediated rejection | NR | Two doses | Disease progression | |
| Zehou et al33 | 67 | M | Nephroangiosclerosis and diabetes mellitus | 2012 | Metastatic melanoma (2014) | Lymph nodes | Everolimus | No rejection | NIL | Four doses | Disease progression | |
| Zehou et al33 | 57 | F | Polycystic kidney disease | 2007 | Lentigo malignant melanoma (2010) | Lymph nodes | Sirolimus and prednisolone | No rejection | NIL | NR | Disease progression | |
| Zehou et al33 | 68 | F | Polycystic kidney disease | 2001 | Metastatic melanoma | Lung, liver, bone and lymph nodes | Everolimus and prednisolone | No rejection | NIL | Two doses | Disease progression |
ICI, immune checkpoint inhibitor; NR, not reported.